OHSU Cancer Institute research discovery opens new window to
understanding chronic myeloid leukemia
ATLANTA – Oregon Health & Science University Cancer Institute
researchers have opened a new window into the roots of chronic
myeloid leukemia (CML).
"We are looking under the surface of CML to understand better where
the cancer is coming from. We have discovered abnormal cells in the
early stem cell population in some CML patients, which don't belong
to the CML clone. These are abnormal cells that are not part of the
CML clone," said Thomas Bumm, M.D., OHSU Cancer Institute member.
This research will be presented at the American Society of Hematology
annual meeting in Atlanta on Sunday, Dec. 9, at 4:30 p.m.
Bumm was looking into Philadelphia Chromosome-negative stem cells –
which he and others had thought would look like normal, healthy
cells, and have normal chromosomes. (It has been known that the
driving force of CML is the Philadelphia Chromosome-positive cancer
cells.)
"But no, these chromosome negative cells are not normal looking. We
are seeing that there are other abnormal cells in the early stem cell
population in the bone marrow of some CML patients that are
Philadelphia Chromosome-negative
deletion of chromosome 7 or a duplication of chromosome 8," explained
Bumm, a fellow in hematology/medical oncology, OHSU School of
Medicine.
It is not known why patients with CML have these abnormal cells and
to what extent. These newly discovered abnormal cells are also seen
in other cancers such as myelodysplastic syndrome.
"We are not yet sure about the extent of this problem. We do hope
though that our studies into the stem cell compartment of CML
patients might help to find new targets for CML therapy to cure this
cancer," Bumm said.
Chronic myelogenous leukemia is a form of blood cancer characterized
by the increased and unregulated growth of predominantly myeloid
cells in the bone marrow and the accumulation of these cells in the
blood.
The next step, although costly, will be to analyze more leukemia
patients as well as healthy bone marrow samples to continue to look
for these new abnormalities.
###
Working with Bumm on this research is Amy E. Hanlon Newell, Ph.D.,
senior research associate in molecular and medical genetics, OHSU
School of Medicine; and Jutta Deininger M.D., senior research
assistant, hematology/medical oncology, OHSU School of Medicine and
an OHSU Cancer Institute member.
The study was performed in the laboratory of Michael Deininger, M.D.,
Ph.D., associate professor of medicine, hematology/medical oncology,
OHSU School of Medicine.
The research is abstract #36
The OHSU Cancer Institute is the only National Cancer Institute-
designated center between Sacramento and Seattle. It comprises some
120 clinical researchers, basic scientists and population scientists
who work together to translate scientific discoveries into longer and
better lives for Oregon's cancer patients. In the lab, basic
scientists examine cancer cells and normal cells to uncover molecular
abnormalities that cause the disease. This basic science informs more
than 200 clinical trials conducted at the OHSU Cancer Institute.
http://www.eurekale
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
StemCells subscribers may also be interested in these sites:
Children's Neurobiological Solutions
http://www.CNSfoundation.org/
Cord Blood Registry
http://www.CordBlood.com/at.cgi?a=150123
The CNS Healing Group
http://groups.yahoo.com/group/CNS_Healing
____________________________________________
«¤»¥«¤»§«¤»¥«¤»§«¤»¥«¤»«¤»¥«¤»§«¤»¥«¤»§«¤»¥«
¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯¯
Earn your degree in as few as 2 years - Advance your career with an AS, BS, MS degree - College-Finder.net.
Change settings via the Web (Yahoo! ID required)
Change settings via email: Switch delivery to Daily Digest | Switch format to Traditional
Visit Your Group | Yahoo! Groups Terms of Use | Unsubscribe
__,_._,___
